JP2018514208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514208A5 JP2018514208A5 JP2017555766A JP2017555766A JP2018514208A5 JP 2018514208 A5 JP2018514208 A5 JP 2018514208A5 JP 2017555766 A JP2017555766 A JP 2017555766A JP 2017555766 A JP2017555766 A JP 2017555766A JP 2018514208 A5 JP2018514208 A5 JP 2018514208A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid construct
- construct according
- signal
- intracellular retention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims description 67
- 108020004707 nucleic acids Proteins 0.000 claims description 55
- 102000039446 nucleic acids Human genes 0.000 claims description 55
- 230000031852 maintenance of location in cell Effects 0.000 claims description 40
- 108091005703 transmembrane proteins Proteins 0.000 claims description 29
- 102000035160 transmembrane proteins Human genes 0.000 claims description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 238000003776 cleavage reaction Methods 0.000 claims description 9
- 230000007017 scission Effects 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 230000014759 maintenance of location Effects 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 4
- 210000003712 lysosome Anatomy 0.000 claims description 4
- 230000001868 lysosomic effect Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 210000003412 trans-golgi network Anatomy 0.000 claims description 4
- 108010027410 Adenovirus E3 Proteins Proteins 0.000 claims description 2
- 241000710190 Cardiovirus Species 0.000 claims description 2
- 102100039371 ER lumen protein-retaining receptor 1 Human genes 0.000 claims description 2
- 102000004961 Furin Human genes 0.000 claims description 2
- 108090001126 Furin Proteins 0.000 claims description 2
- 101000812437 Homo sapiens ER lumen protein-retaining receptor 1 Proteins 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 241000723792 Tobacco etch virus Species 0.000 claims description 2
- 108091005906 Type I transmembrane proteins Proteins 0.000 claims description 2
- 102000003425 Tyrosinase Human genes 0.000 claims description 2
- 108060008724 Tyrosinase Proteins 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 230000012202 endocytosis Effects 0.000 claims description 2
- 210000001163 endosome Anatomy 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 238000004064 recycling Methods 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 230000002132 lysosomal effect Effects 0.000 claims 2
- 101150049689 tyrP gene Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 102000035087 single-pass transmembrane proteins Human genes 0.000 description 1
- 108091005496 single-pass transmembrane proteins Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1507104.6 | 2015-04-27 | ||
| GBGB1507104.6A GB201507104D0 (en) | 2015-04-27 | 2015-04-27 | Nucleic acid construct |
| PCT/GB2016/051164 WO2016174408A1 (en) | 2015-04-27 | 2016-04-26 | Nucleic acid construct |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020117039A Division JP2020171313A (ja) | 2015-04-27 | 2020-07-07 | 核酸構築物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514208A JP2018514208A (ja) | 2018-06-07 |
| JP2018514208A5 true JP2018514208A5 (OSRAM) | 2019-04-11 |
| JP6836515B2 JP6836515B2 (ja) | 2021-03-03 |
Family
ID=53488689
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555766A Active JP6836515B2 (ja) | 2015-04-27 | 2016-04-26 | 核酸構築物 |
| JP2020117039A Withdrawn JP2020171313A (ja) | 2015-04-27 | 2020-07-07 | 核酸構築物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020117039A Withdrawn JP2020171313A (ja) | 2015-04-27 | 2020-07-07 | 核酸構築物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11530420B2 (OSRAM) |
| EP (1) | EP3288968B1 (OSRAM) |
| JP (2) | JP6836515B2 (OSRAM) |
| CN (1) | CN107532176A (OSRAM) |
| AU (1) | AU2016254498B2 (OSRAM) |
| CA (1) | CA2984101A1 (OSRAM) |
| ES (1) | ES2847698T3 (OSRAM) |
| GB (1) | GB201507104D0 (OSRAM) |
| HK (1) | HK1244021A1 (OSRAM) |
| WO (1) | WO2016174408A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| GB201507108D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
| US11279949B2 (en) * | 2015-09-04 | 2022-03-22 | Denovo Biopharma Llc | Recombinant vectors comprising 2A peptide |
| US11440958B2 (en) | 2016-11-22 | 2022-09-13 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
| CN110997719B (zh) | 2017-03-24 | 2020-12-11 | 莱蒂恩技术公司 | 用于用抗cd33免疫疗法治疗癌症的组合物和方法 |
| WO2018182511A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| US11389525B2 (en) | 2017-10-27 | 2022-07-19 | Statens Serum Institut | Polygene influenza vaccine |
| CN108359014A (zh) * | 2018-02-08 | 2018-08-03 | 四川农业大学 | 含有dhav-1 2a1-p的多肽及其介导的多蛋白共表达方法 |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| GB201805918D0 (en) | 2018-04-10 | 2018-05-23 | Autolus Ltd | Cell |
| AU2019326617A1 (en) * | 2018-08-24 | 2021-03-18 | Locanabio, Inc. | FASL immunomodulatory gene therapy compositions and methods for use |
| JP7560882B2 (ja) | 2018-08-29 | 2024-10-03 | ナショナル ユニヴァーシティー オブ シンガポール | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| GB201914611D0 (en) * | 2019-10-09 | 2019-11-20 | Autolus Ltd | Engineered immune cell |
| WO2024197792A1 (en) * | 2023-03-31 | 2024-10-03 | Beijing University Of Chinese Medicine | A complex comprising a cell penetrating peptide and a copi sorting inhibitor and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1183968C (zh) * | 1996-10-23 | 2005-01-12 | 宾夕法尼亚州立大学托管会 | 改良疫苗 |
| SG164383A1 (en) * | 2005-07-21 | 2010-09-29 | Abbott Lab | Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis |
| CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| AU2013349725B2 (en) * | 2012-11-21 | 2016-05-12 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for determination of botulinum neurotoxin biological activity |
| CA2937750A1 (en) * | 2014-02-14 | 2015-08-20 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
| WO2016123010A1 (en) | 2015-01-26 | 2016-08-04 | United States Mineral Products Company | Corrosion resistant spray applied fire resistive materials |
-
2015
- 2015-04-27 GB GBGB1507104.6A patent/GB201507104D0/en not_active Ceased
-
2016
- 2016-04-26 ES ES16720483T patent/ES2847698T3/es active Active
- 2016-04-26 JP JP2017555766A patent/JP6836515B2/ja active Active
- 2016-04-26 US US15/568,859 patent/US11530420B2/en active Active
- 2016-04-26 WO PCT/GB2016/051164 patent/WO2016174408A1/en not_active Ceased
- 2016-04-26 HK HK18103619.5A patent/HK1244021A1/zh unknown
- 2016-04-26 CA CA2984101A patent/CA2984101A1/en not_active Abandoned
- 2016-04-26 CN CN201680024069.5A patent/CN107532176A/zh active Pending
- 2016-04-26 AU AU2016254498A patent/AU2016254498B2/en not_active Ceased
- 2016-04-26 EP EP16720483.3A patent/EP3288968B1/en active Active
-
2020
- 2020-07-07 JP JP2020117039A patent/JP2020171313A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514208A5 (OSRAM) | ||
| JP2018514209A5 (OSRAM) | ||
| Fujii et al. | PA tag: a versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin | |
| JP6836515B2 (ja) | 核酸構築物 | |
| ES2869971T3 (es) | Construcción de ácido nucleico | |
| JP2016533174A5 (OSRAM) | ||
| ZA202006432B (en) | T cell receptors | |
| Cortese et al. | Recombinant human cytomegalovirus (HCMV) RL13 binds human immunoglobulin G Fc | |
| WO2011039508A3 (en) | T-cell receptor | |
| JP2019521643A5 (OSRAM) | ||
| JP7704685B2 (ja) | 抗原結合タンパク質 | |
| Tang et al. | Molecular cloning and localization of human syntaxin 16, a member of the syntaxin family of SNARE proteins | |
| HRP20220080T1 (hr) | Poboljšane imunoglobulinske varijabilne domene koje vežu serumski albumin | |
| WO2017172981A3 (en) | Chimeric antigen receptors targeting cancer | |
| Carrington et al. | Sequence and expression of the glycosyl-phosphatidylinositol-specific phospholipase C of Trypanosoma brucei | |
| IL274547B1 (en) | Modified ligand-gated ion channels and methods of use | |
| JP2019535268A5 (ja) | アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物 | |
| JP2018530315A5 (OSRAM) | ||
| JP2018531624A5 (OSRAM) | ||
| WO2008138649A3 (en) | Signaling peptides | |
| HK1215441A1 (zh) | 人血清白蛋白结合化合物及其融合蛋白 | |
| Forti et al. | Identification of a novel overlapping sequential E epitope (E′) on the bovine leukaemia virus SU glycoprotein and analysis of immunological data | |
| JP2015527074A5 (OSRAM) | ||
| Schwardt et al. | The negative regulator of Borna disease virus polymerase is a non-structural protein | |
| WO2009002939A3 (en) | Autophilic antibodies |